MERCK KGAA

🇩🇪Germany
Ownership
Public
Established
1668-01-01
Employees
62.9K
Market Cap
$84.2B
Website
http://www.merckgroup.com/de
Clinical Trials
Related News

Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)

Phase 1
Completed
Conditions
Osteoarthritis, Knee
Interventions
Drug: Placebo
Drug: M6495
First Posted Date
2018-07-11
Last Posted Date
2020-01-23
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
32
Registration Number
NCT03583346
Locations
🇩🇰

DanTrials ApS, Copenhagen NV, Denmark

Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Test GXR
Drug: Reference GXR
First Posted Date
2018-06-25
Last Posted Date
2020-01-09
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
54
Registration Number
NCT03566810
Locations
🇨🇳

Xuanwu Hospital Capital Medical University, Beijing, China

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Tepotinib
Drug: Omeprazole
First Posted Date
2018-05-22
Last Posted Date
2023-07-28
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
12
Registration Number
NCT03531762
Locations
🇩🇪

Nuvisan GmbH, Neu-Ulm, Germany

Phase I/Ib Multiple Ascending Dose Study in China

First Posted Date
2018-05-14
Last Posted Date
2024-02-23
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
24
Registration Number
NCT03523390
Locations
🇨🇳

Research site, Hangzhou, Zhejiang, China

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Dabigatran Etexilate
Drug: Tepotinib
First Posted Date
2018-04-10
Last Posted Date
2023-08-07
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
20
Registration Number
NCT03492437
Locations
🇩🇪

Nuvisan GmbH, Neu-Ulm, Germany

Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants

First Posted Date
2018-03-16
Last Posted Date
2019-07-16
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
40
Registration Number
NCT03467945
Locations
🇩🇪

Please Contact the Merck KGaA Communication Center, Darmstadt, Germany

A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Metformin/Gliclazide Fixed Combination
First Posted Date
2018-03-16
Last Posted Date
2019-07-08
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
21
Registration Number
NCT03467971
Locations
🇲🇽

CECYPE, Mexico City, Mexico

Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)

Phase 1
Completed
Conditions
Renal Impairment
Interventions
Drug: Evobrutinib
First Posted Date
2018-02-19
Last Posted Date
2019-05-16
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
31
Registration Number
NCT03436394
Locations
🇩🇪

Please Contact the Merck KGaA Communication Center, Darmstadt, Germany

Praziquantel Bioequivalence Study

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Cisticid
Drug: Biltricide
First Posted Date
2018-02-19
Last Posted Date
2019-09-18
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
60
Registration Number
NCT03437447
Locations
🇲🇽

Clínica de Enfermedades Crónicas y de Procedimientos Especiales, Sociedad Civil (SC), México, Mexico

Glucophage Immediate Release (GIR) China Bioequivalence Study

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Test GIR
Drug: Reference GIR
First Posted Date
2018-01-08
Last Posted Date
2019-07-15
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
44
Registration Number
NCT03393208
Locations
🇨🇳

Xuanwu Hospital, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy